Street:Paul Ehrlich Str. 15 D-72076 Tübingen Germany
MaxCard:
About us
Welcome To Our Site!
Synovo's main pharmacology activities are based on assays and models for the selection of drug candidates with improved properties of Absorbtion, Disposition, Metabolism and Elimination (ADME or DMPK). Synovo establishes these parameters using human derived cells, proteins and systems wherever feasible to ensure the relevance of its data to use in man.
Synovo is engaged in projects in the fields of anti-inflammatory and immune suppressive drug optimisation on behalf of clients from the pharmaceutical industry. Synovo is also working in partnership with public sector laboratories to improve its systems and extend its technologies to protein and nucleic acid drugs.
Based in Tübingen, home of one of the best known Universities in Germany, Synovo GmbH benefits from access to cutting edge technology, highly skilled staff and a magnificent location over looking the Schwabian Alps.
The company has 20 full and part-time team members is managed by Dr. Michael Burnet. Michael came to Germany in 2000 after working in early discovery for Zeneca in the UK where he developed a broad interest in chemical biology and its uses to improve small molecule discovery efficiency. For general or corporate enquiries, Michael can be contacted via:
Synovo is a privately held and independant company registered in Tübingen*.
Synovo‘s team works in a new facility provided through the Technology Park Tübingen Reutlingen (TTR) Consortium. The laboratories are equiped with state-of-the-art air handling and climate control to ensure an optimal working environment and environmentally responsible energy use.
Along with sound environmental policies, the company is committed to developing its people and playing a role in the training of students via work experience. Synovo and its team, welcomes contact from schools and community groups and is happy to discuss the role of the pharmaceutical industry in improving our standard of living.
Germany
